Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMZ regimen as front-line treatment in indolent non-follicular B-cell non-Hodgkin lymphoma
2004-002302-30Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Feb 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, mitoxantrone and ibritumomab tiuxetan in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL), marginal zone B-cell lymphoma (MZL) and 1 more, sponsored by Sant'Orsola-Malpighi University Hospital. Started Feb 2006; status: completed.
02
Drugs
fludarabinemitoxantroneibritumomab tiuxetan
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)marginal zone B-cell lymphoma (MZL)low-grade B-cell lymphoma
Beyond the preview
Go deeper on 2004-002302-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002302-30.